Authors: Fokkema, E de Vries, EGE Meijer, S Groen, HJM

Citation: E. Fokkema et al., Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patients, CANC CHEMOT, 45(1), 2000, pp. 89-92

Authors: Fokkema, E Verweij, J van Oosterom, AT Uges, DRA Spinelli, R Valota, O de Vries, EGE Green, HJM

Citation: E. Fokkema et al., A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study, BR J CANC, 82(4), 2000, pp. 767-771

Authors: Groen, HJM Fokkema, E Biesma, B Kwa, B van Putten, JWG Postmus, PE Smit, EF

Citation: Hjm. Groen et al., Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: A non-cross-resistant schedule, J CL ONCOL, 17(3), 1999, pp. 927-932

Authors: Fokkema, E Groen, HJM Bauer, J Uges, DRA Weil, C Smith, IE

Citation: E. Fokkema et al., Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell long cancer, J CL ONCOL, 17(12), 1999, pp. 3822-3827